NasdaqGS:INCYBiotechs
Incyte (INCY) Lands Fresh Clinical Wins, Is It Fully Valued?
Incyte (INCY) stock is drawing fresh attention after a run of clinical and regulatory updates, including pivotal lymphoma data, positive rare disease results, early myeloproliferative neoplasm findings and a favorable Opzelura Medicaid settlement.
See our latest analysis for Incyte.
At a share price of $107.53, Incyte has seen a 19.08% 90 day share price return and a 51.86% 1 year total shareholder return, suggesting momentum has strengthened as recent clinical wins, Japanese approvals and...